Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1

Interventions

Docetaxel 17Surveys and Questionnaires 15pembrolizumab 14Specimen Handling 10Radiotherapy 10Early Intervention, Educational 10Zoledronic Acid 9Interviews as Topic 9olaparib 8Standard of Care 8Psychiatric Rehabilitation 8Therapeutics 7Magnetic Resonance Spectroscopy 7Gemcitabine 7Fulvestrant 7durvalumab 6Paclitaxel 6Nivolumab 6Methods 6Educational Status 6Carboplatin 6enzalutamide 5Trastuzumab 5Radiosurgery 5Exercise 5Cyclophosphamide 5palbociclib 4Taxes 4Sirolimus 4Letrozole 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × CX 5461 × Breast × Clear all
NCT04890613 2026-04-28

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Senhwa Biosciences, Inc.

Phase 1 Recruiting
52 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡